Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
While the focus of microdosing programs is on long-term health and aging, program participants may experience reduced appetite, curbed cravings, and promotion of gradual, sustained weight loss for those aiming to maintain a healthy weight
Research indicates that CagriSema, semaglutide, and cagrilintide all have a fairly similar rate of negative side effects, though cagrilintide produced notably lower rates of gastrointestinal (GI) disorders
Original Peptide products are intended for laboratory and research use only
Despite these setbacks, Pfizer appears committed to the obesity market and continues to progress PF-07976016, a first-in-class, orally delivered small molecule GIP receptor antagonist for treatment of obesity, for which safety and efficacy is currently being evaluated in a dose-ranging Phase II study, (NCT06717425)
Encouraged for better results
US$ 25.18
US$ 23.37
US$ 27.79
